About SAMe
SAMe (S-Adenosylmethionine) is the body's universal methyl donor, essential for synthesis of serotonin, dopamine, and norepinephrine. A 2024 meta-analysis (23 RCTs, 2,183 patients) found SAMe monotherapy significantly superior to placebo (SMD = -0.58) and comparable to antidepressants. Cochrane Review confirmed superiority to placebo and equivalence to TCAs. Faster onset than SSRIs (1–2 weeks). Chemically unstable — enteric-coated tosylate or butanedisulfonate forms required. May trigger mania in bipolar patients.
What SAMe supports
- Comparable to TCAs/SSRIs for depression (23 RCTs, 2,183 patients)
- Universal methyl donor — supports neurotransmitter synthesis
- Faster onset than SSRIs (1–2 weeks vs 4–6 weeks)
How much SAMe to take
Clinical studies typically use 800–1600 mg of SAMe. 800–1,600 mg/day in divided doses. Enteric-coated tablets essential for stability. 2024 meta-analysis (23 RCTs, 2,183 patients) found efficacy comparable to TCAs and SSRIs.
- Effective range
- 800–1600 mg
Clinical evidence
Strong clinical evidence. Meta-analysis of 23 trials (2,183 patients) found efficacy comparable to antidepressants for depression
Examine.com